Aldeyra Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 10
- Market Cap
- $319M
- Website
- http://www.aldeyra.com
- Introduction
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
A Clinical Trial Investigating the Safety and Efficacy of Subjects with Alcoholic Hepatitis (Part 1)
- Conditions
- Alcoholic Hepatitis
- Interventions
- Drug: ADX-629
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06685692
- Locations
- 🇺🇸
Synergry Healthcare, Bradenton, Florida, United States
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Vehicle Ophthalmic Solution
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06493604
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Reproxalap ophthalmic solution (0.25%)Drug: Vehicle ophthalmic solution
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT06424444
- Locations
- 🇺🇸
Core, Inc., Shelby, North Carolina, United States
A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Vehicle Ophthalmic Solution
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT06389214
- Locations
- 🇨🇦
Cliantha Research, Mississauga, Ontario, Canada
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: ADX-629 (Open-label)
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05717920
- Locations
- 🇺🇸
Bexley Dermatology Research, Bexley, Ohio, United States
Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
- Conditions
- Nephrotic Syndrome
- Interventions
- Drug: ADX-629
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Registration Number
- NCT05599815
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Emory University - Pediatric Nephrology, Atlanta, Georgia, United States
🇺🇸Nevada Kidney Disease Hypertension Center (NKDHC), Las Vegas, Nevada, United States
A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels
- Conditions
- Ethanol Intoxication
- Interventions
- Drug: PlaceboDrug: ADX-629
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05487404
- Locations
- 🇺🇸
Medpace Clinical Pharmacology, Cincinnati, Ohio, United States
A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Vehicle Ophthalmic Solution
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05424549
- Locations
- 🇨🇦
Cliantha Research, Mississauga, Ontario, Canada
A Study in Subjects With Retinitis Pigmentosa
- Conditions
- Retinitis Pigmentosa
- Interventions
- Drug: ADX-2191
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05392179
- Locations
- 🇺🇸
Duke Eye Center, Durham, North Carolina, United States
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
- Conditions
- Chronic Cough
- Interventions
- Drug: ADX-629Drug: Placebo
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT05392192
- Locations
- 🇺🇸
Mount Sinai, New York, New York, United States
🇺🇸Cano Research - Hollywood, Hollywood, Florida, United States
🇺🇸ClinCept, Columbus, Georgia, United States